# A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult Participants

> **NCT04410094** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Lazertinib
- **DRUG:** Itraconazole
- **DRUG:** Rifampin

## Key facts

- **NCT ID:** NCT04410094
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-14
- **Primary completion:** 2020-12-30
- **Final completion:** 2021-02-02
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2021-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04410094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04410094, "A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult Participants". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04410094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*